More importantly, the diversity of targeted therapies causing this shared GPX4 dependence suggests that lipid remodeling leading to PUFA enrichment of phospholipids might be a common mechanism associated with therapy resistance that could be pursued as therapeutic target in multiple types of cancer. This evidence concerns the gene GPX4 and cancer.